Skip to main content

Tempest Therapeutics, Inc DEFA14A, filed Nov 16, 2026

Tempest Therapeutics, Inc. (TPST)

Tempest Therapeutics adjourned its reconvened special meeting to December 11, 2026, lacking votes to approve a charter amendment replacing supermajority voting and allowing written consent. A quorum was present, with 74.64% of outstanding shares. AI summary

DEFA14A 2026-11-16
View Original
Added on November 17, 2026